Delphine Hudry1,2, Stéphanie Bécourt3, Giovanni Scambia4,5, Anna Fagotti4,5. 1. Department of Gynecologic Oncology, Depart Oscar Lambret Center, 3 rue Frédérique Combemale, BP307 59000, Lille, France. d-hudry@o-lambret.fr. 2. Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. d-hudry@o-lambret.fr. 3. Department of Gynecologic Oncology, Depart Oscar Lambret Center, 3 rue Frédérique Combemale, BP307 59000, Lille, France. 4. Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. 5. Università Cattolica del Sacro Cuore, Rome, Italy.
Abstract
PURPOSE OF REVIEW: Summarize the writings published in the last 5 years on the management of surgery in the first line of treatment for advanced ovarian cancer. RECENT FINDINGS: For patients with a significant tumor burden, the neoadjuvant chemotherapy therapy (NACT) with interval debulking surgery (IDS) strategy shows comparable efficacy than primary debulking surgery (PDS) in terms of survival in randomized studies with less morbidity. Advanced epithelial ovarian cancer generates more than half cases a recurrence. First-line treatment is based on a chemotherapy regimen combining a platinum-based and a taxane-based, associated with surgery. This review considers papers of last 5 years of timing, thinking tools, and innovation in the management. The choice of strategy, PDS or IDS, would be a personalized recommendation. The challenge is to adapt the timing of the surgery to the patient's characteristics and that of her disease.
PURPOSE OF REVIEW: Summarize the writings published in the last 5 years on the management of surgery in the first line of treatment for advanced ovarian cancer. RECENT FINDINGS: For patients with a significant tumor burden, the neoadjuvant chemotherapy therapy (NACT) with interval debulking surgery (IDS) strategy shows comparable efficacy than primary debulking surgery (PDS) in terms of survival in randomized studies with less morbidity. Advanced epithelial ovarian cancer generates more than half cases a recurrence. First-line treatment is based on a chemotherapy regimen combining a platinum-based and a taxane-based, associated with surgery. This review considers papers of last 5 years of timing, thinking tools, and innovation in the management. The choice of strategy, PDS or IDS, would be a personalized recommendation. The challenge is to adapt the timing of the surgery to the patient's characteristics and that of her disease.
Authors: Alexander Reuss; Andreas du Bois; Philipp Harter; Christina Fotopoulou; Jalid Sehouli; Giovanni Aletti; Frederic Guyon; Stefano Greggi; Berit Jul Mosgaard; Alexander Reinthaller; Felix Hilpert; Carmen Schade-Brittinger; Dennis S Chi; Sven Mahner Journal: Int J Gynecol Cancer Date: 2019-08-15 Impact factor: 3.437
Authors: Ignace Vergote; Corneel Coens; Matthew Nankivell; Gunnar B Kristensen; Mahesh K B Parmar; Tom Ehlen; Gordon C Jayson; Nick Johnson; Ann Marie Swart; René Verheijen; W Glenn McCluggage; Tim Perren; Pierluigi Benedetti Panici; Gemma Kenter; Antonio Casado; Cesar Mendiola; Gavin Stuart; Nick S Reed; Sean Kehoe Journal: Lancet Oncol Date: 2018-11-06 Impact factor: 41.316
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Helena C Bartels; Ailin C Rogers; Veronica McSharry; Ruaidhri McVey; Thomas Walsh; Donal O'Brien; William D Boyd; Donal J Brennan Journal: Gynecol Oncol Date: 2019-07-23 Impact factor: 5.482
Authors: Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Lisa Barroilhet; Kian Behbakht; Andrew Berchuck; Jonathan S Berek; Lee-May Chen; Mihaela Cristea; Marie DeRosa; Adam C ElNaggar; David M Gershenson; Heidi J Gray; Ardeshir Hakam; Angela Jain; Carolyn Johnston; Charles A Leath; Joyce Liu; Haider Mahdi; Daniela Matei; Michael McHale; Karen McLean; David M O'Malley; Richard T Penson; Sanja Percac-Lima; Elena Ratner; Steven W Remmenga; Paul Sabbatini; Theresa L Werner; Emese Zsiros; Jennifer L Burns; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2019-08-01 Impact factor: 11.908
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Anna Fagotti; Maria Gabriella Ferrandina; Giuseppe Vizzielli; Tina Pasciuto; Francesco Fanfani; Valerio Gallotta; Pasquale Alessandro Margariti; Vito Chiantera; Barbara Costantini; Salvatore Gueli Alletti; Francesco Cosentino; Giovanni Scambia Journal: Int J Gynecol Cancer Date: 2020-10-07 Impact factor: 3.437